Stifel Financial’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-15,513
| Closed | -$622K | – | 3375 |
|
|
2023
Q2 | $622K | Sell |
15,513
-84
| -0.5% | -$3.47K | ﹤0.01% | 2390 |
|
|
2023
Q1 | $637K | Sell |
15,597
-143
| -0.9% | -$5.69K | ﹤0.01% | 2373 |
|
|
2022
Q4 | $608K | Sell |
15,740
-171
| -1% | -$8.32K | ﹤0.01% | 2362 |
|
|
2022
Q3 | $847K | Buy |
15,911
+1,071
| +7% | +$59.6K | ﹤0.01% | 2084 |
|
|
2022
Q2 | $866K | Buy |
14,840
+426
| +3% | +$27.9K | ﹤0.01% | 2107 |
|
|
2022
Q1 | $1.1M | Sell |
14,414
-12,094
| -46% | -$806K | ﹤0.01% | 2047 |
|
|
2021
Q4 | $1.59M | Sell |
26,508
-2,317
| -8% | -$128K | ﹤0.01% | 1787 |
|
|
2021
Q3 | $1.61M | Buy |
28,825
+2,889
| +11% | +$167K | ﹤0.01% | 1728 |
|
|
2021
Q2 | $1.57M | Buy |
25,936
+12,785
| +97% | +$809K | ﹤0.01% | 1776 |
|
|
2021
Q1 | $922K | Sell |
13,151
-189
| -1% | -$13.5K | ﹤0.01% | 2043 |
|
|
2020
Q4 | $798K | Sell |
13,340
-68
| -0.5% | -$3.98K | ﹤0.01% | 2014 |
|
|
2020
Q3 | $806K | Sell |
13,408
-7,897
| -37% | -$459K | ﹤0.01% | 1780 |
|
|
2020
Q2 | $1.12M | Buy |
21,305
+13,144
| +161% | +$549K | ﹤0.01% | 1485 |
|
|
2020
Q1 | $273K | Sell |
8,161
-6,089
| -43% | -$253K | ﹤0.01% | 2243 |
|
|
2019
Q4 | $642K | Sell |
14,250
-874
| -6% | -$37.1K | ﹤0.01% | 2106 |
|
|
2019
Q3 | $580K | Buy |
15,124
+767
| +5% | +$30.6K | ﹤0.01% | 2093 |
|
|
2019
Q2 | $629K | Sell |
14,357
-1,974
| -12% | -$83.8K | ﹤0.01% | 2084 |
|
|
2019
Q1 | $625K | Buy |
16,331
+2,904
| +22% | +$113K | ﹤0.01% | 1936 |
|
|
2018
Q4 | $578K | Sell |
13,427
-866
| -6% | -$40.4K | ﹤0.01% | 1866 |
|
|
2018
Q3 | $703K | Buy |
14,293
+5,608
| +65% | +$242K | ﹤0.01% | 1911 |
|
|
2018
Q2 | $280K | Sell |
8,685
-1,039
| -11% | -$35.9K | ﹤0.01% | 2343 |
|
|
2018
Q1 | $304K | Sell |
9,724
-1,118
| -10% | -$39.8K | ﹤0.01% | 2243 |
|
|
2017
Q4 | $494K | Buy |
10,842
+1,475
| +16% | +$58.5K | ﹤0.01% | 1922 |
|
|
2017
Q3 | $353K | Buy |
+9,367
| New | +$377K | ﹤0.01% | 2079 |
|
|
2016
Q1 | – | Sell |
-3,626
| Closed | -$278K | – | 2339 |
|
|
2015
Q4 | $278K | Buy |
+3,626
| New | +$205K | ﹤0.01% | 1955 |
|
|
2015
Q3 | – | Sell |
-4,300
| Closed | -$304K | – | 2334 |
|
|
2015
Q2 | $304K | Sell |
4,300
-6,296
| -59% | -$496K | ﹤0.01% | 1948 |
|
|
2015
Q1 | $942K | Buy |
10,596
+1,022
| +11% | +$104K | 0.01% | 1316 |
|
|
2014
Q4 | $850K | Sell |
9,574
-198
| -2% | -$18.7K | ﹤0.01% | 1348 |
|
|
2014
Q3 | $947K | Sell |
9,772
-3,372
| -26% | -$328K | 0.01% | 1161 |
|
|
2014
Q2 | $1.21M | Sell |
13,144
-1,804
| -12% | -$137K | 0.01% | 1012 |
|
|
2014
Q1 | $1.05M | Buy |
+14,948
| New | +$1.02M | 0.01% | 1049 |
|
Other funds holding PCRX
FCM
SIMG
PM
Stifel Financial's PCRX Position: Q3 2023 in Review
Stifel Financial sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 15,513 shares — an estimated $622K sold.
Stifel Financial first reported a position in PCRX in Q1 2014 and held it in 31 quarters. The position peaked at $1.61M in Q3 2021. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.
- Stifel Financial reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
- Stifel Financial sold 15,513 Pacira BioSciences shares in Q3 2023, an estimated $622K.
- Stifel Financial first reported a position in Pacira BioSciences in Q1 2014 and held it in 31 quarters.
- Stifel Financial's Pacira BioSciences position peaked at $1.61M in Q3 2021.
- 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.
Based on Stifel Financial's 13F filing for Q3 2023, filed 13 Nov 2023.